V1RH8 Inhibitors
V1RH8 inhibitors are a class of chemical compounds designed to selectively interact with the V1RH8 receptor, a protein that is part of a larger family of receptors known for their role in various biological signaling pathways. The V1RH8 receptor, like its family members, is characterized by its ability to bind to specific molecules, which then induces a conformational change in the receptor's structure, leading to a cascade of intracellular events. Inhibitors targeting this receptor are crafted through a rigorous process of chemical synthesis and optimization, with a keen focus on achieving high affinity and selectivity. The structure-activity relationship (SAR) of these inhibitors is a critical aspect of their design, ensuring that they fit precisely within the binding domain of the V1RH8 receptor, much like a key fits into a lock.
The development of V1RH8 inhibitors involves extensive research in molecular biology and chemistry These inhibitors typically feature a complex architecture that allows them to bind effectively to the target receptor and modulate its activity. The specificity of V1RH8 inhibitors lies in their unique chemical interactions with the receptor, which are often mediated by hydrogen bonds, hydrophobic interactions, and van der Waals forces. These interactions are crucial for the inhibitors to achieve their desired effect on the receptor's function. Furthermore, the properties of V1RH8 inhibitors are finely tuned to ensure proper absorption, distribution, metabolism, and excretion profiles, which are essential for their activity within biological systems. The inherent stability of these inhibitors in biological environments is also a significant consideration, as it affects their overall efficacy in interacting with the V1RH8 receptor.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL kinase activity. V1RH8 activity is often upregulated in the presence of aberrant kinase signaling, and by inhibiting these kinases, dasatinib can lead to a decreased functional activity of V1RH8 by reducing the phosphorylation events that promote its signaling. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). V1RH8 is modulated via Rho/ROCK signaling and inhibiting ROCK can reduce V1RH8 activation tied to cytoskeletal rearrangement processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). V1RH8 activity is downstream of PI3K signaling. Inhibition of PI3K leads to a reduction in Akt phosphorylation and subsequent V1RH8 signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK/ERK pathway. By preventing MEK activation, PD98059 indirectly reduces V1RH8 signaling that is modulated by ERK-mediated transcriptional events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which impedes the p38 MAPK pathway involved in inflammatory responses and stress signaling. Inhibition of this pathway can reduce the activity of V1RH8 if it is regulated as part of the cellular response to stress signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of ERK1/2. This can lead to downregulation of V1RH8 activity if V1RH8 is regulated by the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which can decrease V1RH8 activity by disrupting the mTOR signaling pathway that regulates cell growth and proliferation, in which V1RH8 may be involved. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490 is a Janus kinase 2 (JAK2) inhibitor, which can decrease V1RH8 activity if V1RH8 is modulated by JAK/STAT signaling pathways that are active in various cellular processes, including cell growth and differentiation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK) which participates in the regulation of apoptosis. Inhibition of JNK can reduce V1RH8 activity if V1RH8 is involved in apoptotic signaling pathways. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective inhibitor of NUAK family SNF1-like kinase 1 (NUAK1), which influences cell adhesion and motility. If V1RH8 signaling is associated with these processes, inhibiting NUAK1 can reduce V1RH8 activity. | ||||||